Exact Sciences Corporation - Common Stock (NQ:EXAS)

Abbott Laboratories (NYSE: ABT) saw its stock price tumble by nearly 10% in early trading on January 22, 2026, following the release of its fourth-quarter 2025 financial results. Despite meeting...

Topics Earnings

Abbott Laboratories Shares Plunge 10% Following Q4 Revenue Miss and Diagnostics Weakness

January 22, 2026

Abbott Shares Slump as Revenue Miss and Exact Sciences Acquisition Jitters Overshadow Earnings Beat

Topics Economy

January 22, 2026

Abbott Laboratories (NYSE: ABT) saw its shares retreat by 5.8% in early trading on Thursday, January 22, 2026, following the release of its fourth-quarter financial results. Despite delivering an...

Exact Sciences Stock Soars To 4-Year High Even As Wall Street Piles On Downgrades After Abbott Deal — Retail Traders Take Profits ↗

Topics Earnings Economy

November 20, 2025

Via Stocktwits

Halper Sadeh LLC Encourages PEN, EXAS, DBRG, FFIC Shareholders to Contact the Firm to Discuss Their Rights

January 21, 2026

Shareholders should contact the firm as there may be limited time to enforce your rights.

The global Mergers and Acquisitions (M&A) market staged a historic comeback in 2025, with total deal value reaching a staggering $5.1 trillion. This resurgence represents a 44% year-over-year increase,...

$5.1 Trillion Global Surge: CEO Confidence Ignites New Era of M&A Transformation

January 19, 2026

Halper Sadeh LLC Encourages SEE, EXAS, ZEUS Shareholders to Contact the Firm to Discuss Their Rights

Topics Artificial Intelligence Economy Initial Public Offering

January 17, 2026

Shareholders should contact the firm as there may be limited time to enforce your rights

CS Diagnostics (OTCQB: CSDX) Advances Infection Control and Oncology Innovation Plus – IVP, SAFX, JTAI, OCG, BMXI Inside

January 14, 2026

Via AB Newswire

Topics Intellectual Property

The Great Diagnostic Consolidation: How a $25.7 Billion Mega-Deal Ignited a 150% Surge in Healthcare M&A

January 14, 2026

As 2026 begins, the healthcare sector is undergoing its most profound transformation in decades. Driven by a relentless push toward "precision medicine" and the industrialization of artificial...

GRAIL Surges as Canaccord Genuity Sets Ambitious $105 Price Target Following Robust 2025 Growth

Topics Artificial Intelligence

January 13, 2026

In a resounding vote of confidence for the future of multi-cancer early detection (MCED), Canaccord Genuity reiterated its "Buy" rating for GRAIL (Nasdaq: GRAL) on Tuesday, January 13, 2026, setting an...

Adaptive Biotechnologies Surges as Preliminary 2025 Results Signal a Turning Point in MRD Commercialization

January 13, 2026

Shares of Adaptive Biotechnologies (NASDAQ: ADPT) soared on Tuesday, January 13, 2026, after the life sciences company announced preliminary fourth-quarter and full-year 2025 financial results that...

On January 12, 2026, the diagnostic sector witnessed a seismic shift as shares of Biodesix (Nasdaq: BDSX) surged more than 40% in early trading, following the release of preliminary full-year 2025...

Biodesix Shares Rocket 42% on Record FY2025 Results and Path to Profitability

January 12, 2026

Halper Sadeh LLC Encourages EXAS, FRGE, TBHC, FFWM Shareholders to Contact the Firm to Discuss Their Rights

Topics Artificial Intelligence Death

January 09, 2026

Shareholders should contact the firm as there may be limited time to enforce your rights.

Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract...

3 Mid-Cap Stocks We Steer Clear Of

January 08, 2026

"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated...

Stay updated with the stocks that are on the move in today's after-hours session. ↗

January 07, 2026

Via Chartmill

1 High-Flying Stock on Our Watchlist and 2 We Question

January 04, 2026

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps...

3 Unpopular Stocks We Steer Clear Of

December 30, 2025

Exact Sciences, the NSABP Foundation, and the German Breast Group Present Results for the Oncodetect® MRD Test in Early Triple-Negative Breast Cancer at SABCS

December 11, 2025

From Exact Sciences Corp.

Via Business Wire

1 Healthcare Stock for Long-Term Investors and 2 We Avoid

December 10, 2025

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Those leading the charge have realized strong financial performance, and over the past six months, the...

The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro...

Topics Stocks

3 Overrated Stocks That Concern Us

December 03, 2025

A combination of operational improvements and developments at its key rival bolstered the stock recently.

Here's Why Grail Soared, Again, in November ↗

December 02, 2025

The healthcare leader wants to make waves in a potentially highly lucrative market.

This Top Dividend King Just Became an Even Better Buy ↗

November 30, 2025

Halper Sadeh LLC Encourages SEE, EXAS, MRSN Shareholders to Contact the Firm to Discuss Their Rights

November 27, 2025

Shareholders should contact the firm immediately as there may be limited time to enforce your rights

Exact Sciences Reinforces International Leadership in Breast Cancer with Strong Presence at 2025 San Antonio Breast Cancer Symposium

November 24, 2025

From Exact Sciences Corp.

Via Business Wire

Unusual volume stocks are being observed in Monday's session. ↗

November 24, 2025

Let's explore the current happenings on the US markets on Monday. Below, you'll find the stocks exhibiting unusual volume in today's session.

Via Chartmill

Q3 Earnings Highs And Lows: Exact Sciences (NASDAQ:EXAS) Vs The Rest Of The Immuno-Oncology Stocks

November 23, 2025

As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the immuno-oncology industry, including Exact Sciences (NASDAQ:EXAS) and its peers.

Halper Sadeh LLC Encourages EXAS, NVRI, MRUS Shareholders to Contact the Firm to Discuss Their Rights

Topics Artificial Intelligence

November 22, 2025

Shareholders should contact the firm immediately as there may be limited time to enforce your rights

Exact Sciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Exact Sciences Corporation - EXAS

November 21, 2025

From Kahn Swick & Foti, LLC

Via Business Wire

Biggest Stock Movers Today, Nov. 20: PACS, BBWI, & More ↗

November 20, 2025

On a big day for tech stocks, some other less well-known companies saw even larger moves.

The company received a buyout offer from Abbot Labs.

Topics Artificial Intelligence Stocks

Why Exact Sciences Rallied Over 50% This Week ↗

November 20, 2025